Medarex startet durch! - 500 Beiträge pro Seite

[Becool]

Medarex wird bei uns unter der WKN 883040 in Berlin und München gehandelt.

Der Wert hatte ja schon vor einem halben Jahr für Furore gesorgt, als der US-Biopharma-Hersteller ein neues Krebsheilmittel entwickelte, das in der Testphase bei 80 % der Krebspatienten zum Rückgang bzw. Verschinden der Tumore beigetragen hatte. Dann hatte die US-Gesundheitsbehörde weitere Testreihen gefordert, bevor eine Marktzulassung erteilt wird.

Jetzt fliegt der Wert wieder zu alten Kurshöhen, legte nach langem dümpeln um 4 US$ immer weiter zu, gestern plus 15 % auf 6 US$ und heute wieder um 8,5 % auf 6,50 US$.

In der Presse-Info vom Dienstag, die den Kursschub ausgelöst hatte, wobei ich glaube, daß da noch einiges mehr in der Pipeline steckt. Stellt Euch das vor: Dank Medarex wird Krebs heilbar und die Anleger dabei noch reich!

Hier nun die Presse-Info:


Tuesday August 31, 7:31 am Eastern Time
Company Press Release
SOURCE: Medarex, Inc.
Medarex Signs Development Agreement with Gilead for Anti-CTLA-4 Therapeutics
CTLA-4 Blockade May Provide Novel Treatment for Cancer and Infectious Diseases
ANNANDALE, N.J., Aug. 31 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX - news) announced today that it has obtained an exclusive sublicense from Gilead Sciences, Inc. (Nasdaq: GILD - news) to the CTLA-4 Blockade intellectual property rights owned by University of California, Berkeley. Using its proprietary HuMAb-Mouse(TM) technology, Medarex has created fully human, high-affinity antibodies that inhibit CTLA-4, an immune system modulator. Medarex also has an option under the sublicensing agreement to pursue certain other non- antibody-based methods of blocking CTLA-4.
CTLA-4, a receptor protein found on the surface of T-cells, is believed to suppress the attack by immune system killer cells. As a novel therapeutic technology, blocking CTLA-4 may allow the immune system to recognize and more vigorously attack foreign pathogens and cancers, including prostate cancer.
In studies conducted at UC Berkeley, James P. Allison, Ph.D., Professor of Immunology, Director of the Cancer Research Institute, and Howard Hughes Medical Investigator, demonstrated that the blockade of CTLA-4 using antibodies can lead to the rejection of cancerous tumors in mice (see Science, March 22, 1996; 271: 1734-6). Dr. Allison and UC Berkeley have obtained a number of patents for the blockade of CTLA-4, which Medarex has sublicensed for considerations, including milestone payments that pass through to UC Berkeley and a royalty split between UC Berkeley and Gilead on future product sales.
``This agreement is an exciting transfer of basic research into the private sector to hopefully lead to the development of drugs useful for the treatment of human disease,`` said Dr. Allison. ``We have shown that CTLA-4 Blockade can elicit a potent anti-tumor effect in many different mouse tumor models and seems to be generally useful in enhancing immune responses. CTLA-4 Blockade could be used therapeutically by itself or in combination with other approaches, such as vaccines.``
``We are very pleased that Medarex is advancing the development of CTLA-4 in prostate cancer. The cancer vaccines undergoing clinical development at this time for prostate cancer may benefit from a significant increase in activity with this novel treatment,`` said Dr. Howard Soule, Executive Vice President and Chief Scientific Officer of CaP CURE, The Association for the Cure of Cancer of the Prostate. ``CaP CURE has been pleased to support the basic work of Dr. Allison that has resulted in the discovery and development of this very interesting drug candidate.``
``Dr. Allison`s groundbreaking work in immunology has laid the foundation for a new approach to cancer immunotherapy,`` said Donald L. Drakeman, Ph.D., President and CEO of Medarex. ``We are excited about the potential application of this technology to many disease states including cancer, infectious diseases and autoimmune conditions. We have utilized our HuMAb-Mouse technology to create fully human, high-affinity antibodies to exploit Dr. Allison`s CTLA-4 Blockade discovery.``
Medarex is a biopharmaceutical company developing monoclonal antibody- based therapeutics to fight cancer and other life-threatening and debilitating diseases. The Company has developed a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse(TM) system for the creation of high-affinity human antibodies; Bispecific antibodies, which enhance and direct the body`s own immune system to fight disease; and immunotoxin technology. Medarex has seven products in clinical development for the treatment of cancers and leukemia, autoimmune diseases and ophthalmic conditions. Through its GenPharm subsidiary, Medarex creates and develops human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about the company visit its web site at http://www.medarex.com.
Gilead Sciences, headquartered in Foster City, CA, is an independent biopharmaceutical company that seeks to provide accelerated treatment solutions for patients and the people who care for them. The Company discovers, develops, manufactures and commercializes proprietary therapeutics for challenging infectious diseases (viral, fungal and bacterial infections) and cancer. Gilead maintains research, development or manufacturing facilities in Foster City, CA, Boulder, CO, San Dimas, CA, and Cambridge, UK, and sales and marketing organizations in the U.S., Europe and Australia. Gilead common stock is traded on The Nasdaq Stock Market under the symbol GILD. For more information about the company visit its web site at http://www.gilead.com.
Certain statements in this press release consist of forward-looking statements that involve risks and uncertainties including, but not limited to, uncertainties regarding the development of new products and business opportunities, and the continuation of business partnerships. Actual results, events or performance may differ materially.
SOURCE: Medarex, Inc.

[Becool]

Warum findet bei dem Wert bei uns nur alle paar Tage ein äußerst geringer Handelsumsatz statt? In USA gingen heute schon wieder fast 100.000 Stück über die Börsentheke bei einem Kursanstieg um über 6 % auf 6,25 US-Dollar (= ca. 6 Euro) In Berlin und München notiert das Papier immer noch bei 5,40 bzw. 5,50 Euro und trotz des Scnäppchenkurses will es wohl keiner haben - gehandelte Stück: 0!

Kann mir jemand dafür eine Erklärung geben? Verpennen die deutschen Anleger vielleicht gerade satte Gewinnchancen?

[SirToby]

Naja, wer kennt bei uns schon diese Aktie? Ich glaube nicht, daß wenn in den USA lediglich 100.000 Stück umgehen, der Bekanntheitsgrad bei usn hoch genug ist, um ausreichend viele Anleger davon zu begeistern und einen liquiden Handel zustande kommen zu lassen.

[Klaus Meier]

ich habe nur ein paar zum zocken
aber bei uns fast null handel wär da nicht limiiert beim kauf der zahlt drauf.
siehe heute
MEDAREX INC. SHARES DL -, 01 Berlin 883040 6,75 +1,35 +25,00%

[asienfreund]

Jetzt hat sich der Wert wohl in D erledigt.

[Becool]

Wie meist Du das Asienfreund? Trotz erneut niedriger Umsätze ist Medarex heute bei uns um über 20 % in Berlin und München auf ein neues 12-Monatshoch von 6,60 bzw. 6,70 Euro weiter nach onen gesprungen. Sieht doch wohl eher so aus, daß die Party erst losgeht! Von wegen, der Wert hat sich in D erledigt oder habe ich Dich mißverstanden?

[Becool]

Jetzt notiert die Biotech-Rakete nach gestern 7,50 US$ bei den Amis heute bereits bei 7,50 Euro in Berlin und sogar 7,60 Euro in München.

Die Party geht weiter!

[Becool]

Am Freitag schloß der Wert in Amiland auf einem neuen 52-Wochen-High bei 7,94 US$, lag sogar im Handelsverlauf auf einem Zwischenhoch von 8 US$, bei uns 7,30 bzw. 7,50 Euro in München und Berlin. Zweistellige Kurse sollten nur eine Frage der Zeit sein, vielleicht schon diese Woche, wenn neben den Biopharma-Insidern auch die breite Börsen-Öffentlichkeit die riesige Gewinnchance erkannt hat.

Mehr Infos findet Ihr unter: http://finance.yahoo.com/q?s=MEDX&d=t mit Kursen, Charts, aktuellen Medarex-News und einem speziellen Medarex-Board unter "Msgs" im Kopf der Kursübersicht.

[Becool]

Interessiert sich denn hier wirklich niemand für den Wert, der innerhalb eines Monats um über 100 % gestiegen ist? Auch heute wieder auf 7,90 Euro in Berlin - und damit erneut ein neues 52-Wochen-Hoch! Doch zu dem allgemeinen Desinteresse hier im Board passen weiterhin auch die Umsätze: jeweils weniger als 1.000 Stück sowohl in Berlin als auch in München! In USA wurden am Freitag immerhin 750.000 Stück gehandelt.

Hat denn außer mir hier niemand eine Meinung zu so einem heissen Wert? Irgendwie frustriert mich das. Ich poste hier, um zu diskutieren, zum Meinungsaustausch und zur Erweiterung meines Kenntnisstandes. Bitte, eine Firma, die vielleicht die Lizenz zur Krebsheilung in der Hand hält, hat es doch verdient, daß darüber gesprochen wird. In Erwartung Eurer regen Antworten ...

... manchmal nicht mehr so ganz Becool!

[Becool]

Und noch immer führe ich Selbstgespräche zu Medarex. Aber sicher nicht mehr lange, denn der nachfolgende Artikel aus dem Boston Globe von gestern wird für Gesprächsstoff sorgen und den Medarex-Kurs heute an der Nasdaqu und dann auch zwangläufig bei uns zu neuen Alltime-Highs fliegen lassen:

Hab ich gerade im Medarex-Board unter yahoo.com gefunden - Jubel-Pressebericht über Medarex in der Sonntagsausgabe des Boston Globe. Das wird den Kurs von Medarex heute an der Nasdaqu und auch bei uns (WKN 883040 in Berlin und München) weiter nach oben katapultieren, vielleicht schon in den zweistelligen Bereich. Wer zu spät kommt, den bestraft der Börsenkurs!


Immune Therapy Developed at UC Berkeley is Being Readied for Clinical Trials Against Prostate Cancer and Melanoma
By Ascribe, 09/09/99 12:36
Immune Therapy Developed at UC Berkeley is Being Readied for Clinical Trials Against Prostate Cancer and Melanoma

BERKELEY, Calif., Sept. 9 (AScribe) -- A promising new cancer therapy developed at the University of California, Berkeley, has caught the eye of cancer researchers, who are readying it for human trials sometime next year.

Unlike other immune therapies that stimulate the body`s immune system to attack tumors, this technique releases a natural brake on the immune system to unleash an assault on the cancer.

So far, the therapy has been tried with impressive results in animals with melanoma and prostate cancer. The drug company Medarex, Inc., of Annandale, New Jersey, announced last week that it will make the drug and spearhead human trials to treat these cancers. It signed a sublicensing agreement with Gilead Sciences, Inc., of Foster City, Calif., which has an exclusive license to the patent covering the technology from UC Berkeley.

``This agreement is an exciting transfer of basic research into the private sector to hopefully lead to the development of drugs useful for the treatment of human disease,`` said immunologist James Allison, professor of molecular and cell biology at UC Berkeley and the developer of the technology. The drug is an antibody that blocks a receptor called CTLA-4 on T cells, the cancer-killing cells of the immune system.

``We have shown that CTLA-4 blockade can elicit a potent anti-tumor effect in many different mouse tumor models and seems to be generally useful in enhancing immune response,`` Allison said.

``CTLA-4 blockade could be used therapeutically by itself or in combination with other approaches, such as vaccines.``

Allison is director of the Cancer Research Laboratory and an investigator in the Howard Hughes Medical Institute at UC Berkeley.

Medarex has used its patented technique for creating antibodies to make fully human, high-affinity antibodies that inhibit the CTLA-4 receptor. The company hopes to test the antibodies not only against cancer, but also against infectious diseases and autoimmune conditions.

``There are a lot of ways to turn on or stimulate the immune system, but this approach focuses on a switch that`s not being turned off,`` said Eric Small, an associate professor of urology at UC San Francisco who plans to conduct preliminary prostate cancer trials. ``In terms of immune therapies against cancer, this is the hottest thing going.``

Allison thinks that the CTLA-4 receptor is important in shutting down the body`s autoimmune response - that is, making sure the body doesn`t attack its own tissues. Since cancers arise from a person`s own cells, they survive because of the body`s reluctance to attack itself.

``The immune system develops tolerance to the body`s own tissue through the thymus gland, which takes care of recognizing the molecules that deal with routine chores common to all cells in the body - nutrient uptake and metabolism, energy production , and cell division - and preventing an immune attack against them,`` Allison explained. ``However, the thymus doesn`t see much of the peripheral tissue, the more specialized tissues like the skin. We think that the immune system is capable of reacting against these tissues, though normally they are below the immune system`s radar. We are bringing them onto the radar screen.``

When the CTLA-4 receptor is blocked, the T cells of the immune system suddenly begin to chip away at tumors. In 1996, Allison and his team reported in the journal Science that injection of antibodies to CTLA-4 led mice to reject tumors.

``In general, we can`t launch an immune response against cancer - the cancer is ourselves,`` Small said. ``But Allison`s work shows that our body does have the capacity to do so, and his therapy makes this more robust.``

Recently, in the August issue of the Journal of Experimental Medicine, Allison and his colleagues reported that injection of anti-CTLA-4 antibodies together with a tumor cell vaccine genetically engineered to produce a growth factor that stimulates the immune system was effective 80 percent of the time in curing mice with experimentally created melanomas, an often deadly type of skin cancer. A tumor cell vaccine is created by surgically removing tumor cells, inactivating them, and then reinjecting the cells to stimulate rejection of the tumor, much like someone can be vaccinated against chicken pox. The cells also had a gene inserted in them to produce the hormone GM-CSF (granulocyte-macrophage colony stimulating factor), which boosts the immune system.

``It seems that T cells are trying to make an effective immune response, but can`t,`` Allison said.

Cancer cells that had migrated to the lung also were taken out by the combination therapy, indicating that the technique may help deal with metastases, that is, cancers that spread from the original site. Interestingly, the mice who survived subsequently were immunized against a second injection of melanoma cells, indicating that the treatment has a protective effect as well.

Similarly, preliminary results suggest that blocking CTLA-4 may be effective in treating prostate tumors in mice.

``The combination therapy seems very, very powerful, and I think it has a bright future,`` Small said. ``But we first have to complete Phase I clinical trials to show the safety and effectiveness of CTLA-4 blockade alone in humans.``

According to Allison, tumors by themselves don`t incite a T-cell attack because T cells respond to the push and pull of two different receptors - what he terms ``yin and yang`` receptor molecules. One, a receptor called CD28, triggers an attack while the other, CTLA-4, suppresses it. Both are activated by key-like molecules called B7-1 and B7-2 when presented along with a tumor antigen by so-called antigen presenting cells. Antigens are molecules sported by tumor cells that advertise they are abnormal.

Apparently, when both B7-1 and B7-2 are present, the negative effect of CTLA-4 is stronger than the positive effect of CD28, and the T-cells basically ignore tumor cells, allowing them to grow unchallenged.

Blocking the CTLA-4 receptor thus removes the brake on the T cell and allows it to attack the tumor.

Because CTLA-4 blockade apparently unleashes an autoimmune attack against the tumor, the treatment sometimes may cause the immune system to attack normal tissue as well. In the mice they treated for melanoma, for example, Allison and his colleagues observed that the immune system sometimes attacked and eliminated melanin containing skin cells, turning the mice white. This condition, called depigmentation, occurs in many patients treated for melanoma, and correlates with an improvement in the patient`s condition.

Because of possible autoimmune reactions, Allison said, the first clinical trials likely will involve treatment of cancers of organs that are not vital: pigmented skin cells, the source of melanomas; the prostate; the breast and ovaries.

``We don`t really think this will be a problem, because we only treat mice for a week,`` Allison said. ``That`s the beauty of this - we are activating the immune system, basically trying to get T cells to go on the attack for a while and ambush the tumor, and then we let the immune system go back to normal. Hopefully, that will be enough for lasting immunity to the cancer.``

Medarex, a biopharmaceutical company developing monoclonal antibody-based therapeutics, is enthusiastic about the therapy.

``Dr. Allison`s groundbreaking work in immunology has laid the foundation for a new approach to cancer immunotherapy,`` said Donald L. Drakeman, president and CEO of Medarex, in a statement issued Aug. 31.

``We are excited about the potential application of this technology to many disease states including cancer, infectious diseases and autoimmune conditions,`` he said.

Clinicians like Small are equally excited.

``Generally, immune therapies for prostate cancer have been underexplored,`` Small said. ``Our work suggests that immune modulation is an important means of attacking prostate cancer, and this antibody may prove to be the most significant addition to our armamentarium.``

The work of Allison and his colleagues has been supported by the National Cancer Institute of the National Institutes of Health, the Howard Hughes Medical Institute and by CaP CURE, The Association for the Cure of Cancer of the Prostate.

[Becool]

Und schon wieder neues 12-Monatshoch vorhin bei 9 US$ an der Nasdaq - und bei uns Alltimehigh von 8,30 Euro in Berlin! Interessiert aber hier wohl niemand. Schade eigentlich. Ich bin jedenfalls seit einiger Zeit dabei und gut im plus. Denke aber, da wird noch einiges kommen, wie auch die "Interessierten" im Medarex-Board bei yahoo.com vermuten auf jeden Fall bald im zweistelligen Kursbereich.

[JJ Trader]

Be cool Becool,

die Story klingt ganz gut. Auch die Marktkapitalisierung ist noch recht niedrig. Ich habe auch ein paar Stück eingesammelt.

grüsse
JJ

[Risky]

Hallo Freunde,
bin bei 6,70 Euro eingestiegen. Aktie hat noch einiges Spiel nach oben. Produkte stimmen und liegen gut in der Zeitachse. Aktie wird noch viel Freude machen. Gruß Risky

[Ybbob]

Servus Becool,

danke für Deinen Tip, ich werde morgen mit Einsteigen.

Viel Glück

Bobby

[Becool]

Hi Ybbob,

hoffe, Du bist schon drin, denn der Kurs notiert bereits über 9 Euro. Im Moment würde ich mit dem Einstieg eher etwas abwarten, bis Gewinnmitnahmen kommen. Könnte natürlich auch ein Fehler sein, wenn der Zug erstmal richtig in Fahrt kommt.

Allen anderen Danke für Eure Postings, hatte schon befürchtet, daß ich in einem Eremiten-Thread mit Medarex in Einsamkeit dahinsiechen müßte.

[SPIRIT]

hy
ich hab heutversucht 450 stk. medarex zu 9 € zu bekommen
kann ich irgendwo sehen obs geklappt hat?
intraday kursentwicklung mit stückanzahl?
wäre dankbar dafür dann wüsst ich heute ob ich mich ärgern soll oder weinen

ein dankender SPIRIT

[Becool]

Hi SPIRIT,
versuch`s mal bei comdirect.de im informer2. Gib die WKN 883040 ein, geh` auf den Chart-Button und dort auf Intraday. Du siehst dann im oberen Chart den Kursverlauf auf einer Zeitachse und in einem zweiten Chart darunter die jeweils gehandelten Stückzahlen. Dabei ist natürlich nie sicher, ob Deine Order in den Zahlen enthalten ist, insbesondere wenn es mehr Kauf- als Verkaufsangebote gegeben hat.

Ganz genau sagen, kann es Dir Deine Bank, die sofort nach Order-Ausführung eine Online-Bestätigung erhalten.

[SPIRIT]

so jetzt krieg ich sie oder hab sie schon um 9 € und dann fällt das zeug.
hoffe es sind nur gewinnmitnahmen nach dem fulminanten anstieg und keine trendwende

wiedermal hoffender SPIRIT

[Becool]

Was ist denn da heute in Amiland los, begreife ich nicht, für Gewinnmitnahmen ist mir der Kursrückgang schon wieder zu stark. Na ja, schaun mer mal.

[Ybbob]

Servus Becool,

ist mir jetzt schon das zweite mal passiert, dass wenn ich eingestiegen war die Kurse purzelten. So ein Mist. Aber ich galaube an die Aktie, bei mehr als 30% Verlust werde ich sogar nachkaufen.

Buy or die.

Gruss Bobby

[hiddenclaim2]

Glückwunsch an alle MEDX longs.
Wie heiß diese Aktie ist sieht man an der Reaktion
auf die heutige relativ harmlose News.
+12% bis jetzt

News:
http://biz.yahoo.com/prnews/990923/nj_medarx__1.html

PS: Bin leider nicht investiert

Gruß hd2

[Ybbob]

Der Zug kommt wieder in Fahrt, jetzt aufspringen oder sich in einem Monat vor die Schienen schmeissen.

Viel Glück

[Ybbob]

Hier noch ein kleiner Nachtrag aus USA,


ANNOUNCES MULTI-TARGET HUMAB-MOUSE ANTIBODY DEVELOPMENT AGREEMENT WITH AMGEN

ANNANDALE, N.J., Sep 23, 1999 /PRNewswire via COMTEX/ -- Medarex,
Inc. (Nasdaq: MEDX) announced today that it has signed a five year
antibody development agreement with Amgen, Inc. (Nasdaq: AMGN). Under
the agreement, Medarex will use its proprietary HuMAb-Mouse(TM)
technology to generate fully human monoclonal antibodies to multiple
targets for Amgen. In return, Medarex will receive research and
development payments from Amgen and could receive additional fees and
milestone payments plus royalties on future product sales. Amgen will
be responsible for product development, manufacturing, and marketing of
any products developed through the collaboration.

"We are very pleased to have the opportunity to work with Amgen, a
global leader in biotechnology and our thirteenth corporate partner
utilizing the HuMAb-Mouse technology to create novel human antibodies,"
said Donald L. Drakeman, President and CEO of Medarex. "Our HuMAb-Mouse
technology continues to attract attention from companies worldwide."

Medarex`s HuMAb-Mouse technology is a transgenic mouse system that
creates high-affinity, fully human antibodies instead of mouse
antibodies. Using standard, well proven laboratory techniques,
scientists can produce these antibodies in a matter of months. Through
its GenPharm subsidiary, Medarex creates and develops human antibodies
for itself and others, offering a full range of antibody development
capabilities, including pre-clinical and clinical manufacturing
services.

Medarex is a biopharmaceutical company developing monoclonal antibody-
based therapeutics to fight cancer and other life-threatening and
debilitating diseases. The Company has developed a broad platform of
patented technologies for antibody discovery and development, including
the HuMAb-Mouse(TM) system for the creation of high-affinity human
antibodies; Bispecific antibodies, which enhance and direct the body`s
own immune system to fight disease; and immunotoxin technology. Medarex
has seven products in clinical development for the treatment of cancers
and leukemia, autoimmune diseases and ophthalmic conditions. For more
information about the company visit its web site at
http://www.medarex.com.

Certain statements in this press release consist of forward-looking
statements that involve risks and uncertainties including, but not
limited to, uncertainties regarding the receipt of future payments and
the continuation of business partnerships. Actual results, events or
performance may differ materially.

Gruß Bobby

[CountZero]

Kennt jemand von euch die Zulassungsbestimmung für Krebsmedikamente in den Staaten? Wie lange dauert die durchschnittliche Dauer von der 2. klinischen Testphase bis zur Markteinführung?

Wenn die Krebsmedikamente von Medarex in den Handel kommen, wird denen das Zeug aus den Händen gerissen. Es erlaubt gezielte Strahlentherapie, ohne das sich die umliegenden gesunden Zellen aus Sympathie zu den Krebszellen gleich mit zerstören. Es wird den Krebs nicht besiegen, aber es wird ein großer Schritt in die Richtung getätigt.

Der Count

[allesaufeinmal]

Die Top-Internetadresse http://www.boerse-research.de



mit allen wichtigen Direktlinks(weit über 1000) zu
onlinebanking
discountbroker
alle börsenplätze
aktientips
fusionen
neuemissionen
wirtschaftsinfo & newsdienste
otc-werte
us - trading
charts
börsenlexika
optionen & futures
internetaktien
investmentfonds
realtime kurse
wirtschaftspresse
anlegerschutz
splits
ratings
finanz und börsensites
insider
earnings
researchsites
börsenspiele
börsensoftware
neuer markt
eurostoxx
smax
alle indizes
börsenboards
daytrading
etc.etc.etc.





hier findet ihr endlich alle hotlinks zu den who´s who
der börse übersichtlich auf einer einzigen adresse.
unbedingt ausprobieren, das suchen im web hat ein ende !!!!!!
einfach direkt auf link klicken

http://www.boerse-research.de

und unbedingt euern favoriten hinzufügen.
wenn zufrieden ,bitte weiterempfehlen!
danke!

[JSK]

Hallo Countzero,

von Phase II bis zur Markteinführung können Jahre vergehen:

es folgt Phase III klinische Prüfung mit hinreichend und sorgfältig ausgewählten Patienten und dann erst die Einreichung bei der FDA und ggf. die Zulassung.
Dann fehlt nur noch der Vertrieb und Marketing, falls das Geld noch reicht...

[CountZero]

Small Caps Online Group LLC stuft Medarex als "BUY" ein.

http://biz.yahoo.com/bw/991102/ny_smallca_3.html

Research:
http://www.smallcapsonline.com/

[JSK]

To BUY or not to BUY ,

Medarex= Mäuse mit Mäusen machen.

Im Biotechbereich empfehle ich BB Biotech oder eigene solide Informationen, sonst wird das nix ...

[CountZero]

Die Mäuse regen zumindest die Fantasie der Amis an. Der Chart zeigt deutlich Richtung Norden.



In USA wieder +10,6%. In Deutschland sind die Umsätze viel zu gering, als das hier die Kurse gleich nachziehen. Ich habe aber keine weiteren News gefunden, warum der Kurs in USA so anzieht. Aber vielleicht hört dort jemand die Mäuse husten.

[CountZero]

Neue Quartalszahlen sind da. Ich stelle diese einfach ohne weiteren Kommentar hier rein.

Medarex Announces Third Quarter Financial Results

ANNANDALE, N.J., Nov. 10 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX)
today announced its third quarter results for the three-month period ending
September 30, 1999. During this period, the Company reported revenues of
$1,314,000 and a net loss of $5,086,000, or $0.16 per share. These results
compare with revenues of $1,256,000 and a net loss of $5,564,000, or $0.22 per
share, for the same period in 1998. The loss for the quarter ended September
30, 1998 includes $320,000 of non-cash interest expense associated with the
accounting treatment for the acquisition of GenPharm International, Inc.
("GenPharm".
The Company also reported revenues for the nine-month period ended
September 30, 1999 of $8,341,000 and a net loss of $10,445,000 or $0.33 per
share. These results compare with revenues of $4,660,000 and a net loss of
$15,770,000 or $0.67 per share for the same period last year. The revenue
increase for the nine months ended September 30, 1999 was principally the
result of licensing revenue of $5,242,000 from GenPharm`s HuMAb-Mouse(TM)
business, an increase of $3,568,000 from the nine-month period ended
September 30, 1998. The loss for the nine-month period ended September 30,
1998 includes $1,521,000 of non-cash interest expense associated with the
accounting treatment for the acquisition of GenPharm.

Medarex`s third quarter highlights included:

-- A multi target collaboration with Eos Biotechnology, Inc. for the use
of the Company`s HuMAb-Mouse technology to develop fully human
antibodies.
-- An announcement by FibroGen, Inc. regarding the formation of a
collaboration with Taisho Pharmaceutical Co., Ltd. based on fully human
antibodies to CTGF developed for FibroGen by Medarex utilizing the
Company`s HuMAb-Mouse technology.

-- A multi target collaboration with Amgen, Inc. for the use of the
Company`s HuMAb-Mouse technology to develop fully human antibodies.

Medarex is a biopharmaceutical company developing monoclonal
antibody-based therapeutics to fight cancer and other life-threatening and
debilitating diseases. The Company has developed a broad platform of patented
technologies for antibody discovery and development, including the HuMAb-Mouse
system for the creation of high-affinity human antibodies; Bispecific
antibodies, which enhance and direct the body`s own immune system to fight
disease; and immunotoxin technology. Medarex has seven products in clinical
development for the treatment of cancers and leukemia, autoimmune diseases and
ophthalmic conditions. For more information about the Company, visit its web
site at http://www.medarex.com.
Certain statements in this press release consist of forward-looking
statements that involve risks and uncertainties including, but not limited to,
uncertainties regarding the progress of on-going clinical development. Actual
results, events or performance may differ materially.

MEDAREX, INC.
Consolidated Statements of Operations
(unaudited)
(In thousands, except share data)

Three Months Ended Nine Months Ended
September 30, September 30,

1999 1998 1999 1998

Sales $45 $53 $532 $574
Grants, contract and
license revenues 1,269 1,203 7,809 4,086
Total revenues 1,314 1,256 8,341 4,660

Costs and expenses:
Cost of sales 27 25 183 472
Research and
development 4,998 5,156 15,166 16,106
General and
administrative 1,629 1,415 4,245 3,619

Operating loss (5,340) (5,340) (11,253) (15,537)

Interest and
dividend income 256 440 814 1,640

Interest expense 2 322 6 1,531
Pre tax loss (5,086) (5,222) (10,445) (15,428)
Provision for
income taxes 0 342 0 342
Net loss $(5,086) $(5,564) $(10,445) $(15,770)
Basic and diluted net
loss per share $(.16) $(.22) $(.33) $(.67)
Weighted average shares
outstanding - basic
and diluted 32,144,114 25,815,038 31,774,055 23,405,584

Condensed Consolidated Balance Sheets

September 30, December 31,
1999 1998
(unaudited)
Current assets, principally
cash, cash equivalents, note
receivable and
marketable securities $22,222 $36,525
Property, plant and
equipment, net 3,232 3,339
Investments in, and
advances to affiliate 549 561
Other assets 1,778 1,810
$27,781 $42,235

Current liabilities $3,213 $6,944
Other liabilities 29 62
Stockholders` equity 24,539 35,229
$27,781 $42,235

SOURCE Medarex, Inc.

[CountZero]

Diese Nachricht hat die Aktionäre in USA beflügelt. Am Freitag stieg der Kurs auf 10 $. In D gilt immer noch ein Spottpreis von 8.50 Euro. Bin mal gespannt wie es weiter geht.



ANNANDALE, N.J., Nov. 11 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX)
announced today that it has received a one million dollar technology access
fee under its global licensing arrangement with Novartis involving Medarex`s
HuMAb-Mouse(TM) technology. This fee was paid in the form of an equity
purchase. During the first year of the agreement, Novartis has taken four
target licenses, in a variety of disease areas. One antibody has been
designated as a development candidate by Novartis. Under the terms of the
agreement, Novartis has the rights to use the HuMAb-Mouse technology
throughout the entire Novartis organization for an unlimited number of targets
for up to ten years.
Current expectations are that the HuMAb-Mouse technology access fees,
license fees and milestone payments could exceed $50 million, exclusive of
royalties. Altogether, Novartis has made payments in excess of $3 million,
primarily in the form of equity purchases.
"Novartis` broad use of the HuMAb-Mouse will help both companies maximize
the value of this technology," said Donald L. Drakeman, President and CEO of
Medarex.
Medarex currently has thirteen corporate partners based on its fully human
monoclonal antibody technology with numerous global pharmaceutical and
biotechnology companies, including Amgen, Bristol Myers Squibb, Centocor,
Inc., Eisai Co. Ltd., Immunex Corporation and Schering AG, Germany
Medarex is a biopharmaceutical company developing monoclonal
antibody-based therapeutics to fight cancer and other life-threatening and
debilitating diseases. The Company has developed a broad platform of patented
technologies for antibody discovery and development, including the HuMAb-Mouse
system for the creation of high-affinity human antibodies; Bispecific
antibodies, which enhance and direct the body`s own immune system to fight
disease; and immunotoxin technology. Medarex has seven products in clinical
development for the treatment of cancers and leukemia, autoimmune diseases and
ophthalmic conditions. For more information about the company visit its web
site at http://www.medarex.com.

Certain statements in this press release consist of forward-looking
statements that involve risks and uncertainties including, but not limited to,
uncertainties regarding the receipt of future payments and the continuation of
business partnerships. Actual results, events or performance may differ
materially.

SOURCE Medarex, Inc.

[Klaus Meier]

MEDAREX INC. SHARES DL -, 01 Berlin 883040 11,00 +2,50 +29,41%
sieht doch gut aus -

[CountZero]

Und das scheint dafür der Grund zu sein. Die Vorbörse in den USA hat schon so etwas angekündigt.

Genmab Receives Loan Commitment from Danish Growth Fund for DKK 48.4 Million
COPENHAGEN, Denmark, Nov. 15 /PRNewswire/ -- Genmab A/S announced that it
has received a loan commitment from the Danish Growth Fund for
DKK 48.4 Million (approximately US$7 million). Genmab plans to use the
proceeds from this loan to support the ongoing development of its first
three human antibody products.
Genmab`s initial development projects include an antibody to CD-4, which
is already in clinical trials to treat rheumatoid arthritis. Genmab is also
developing an antibody against Interleukin 15, a cytokine implicated in a
number of inflammatory diseases. This project is being carried out in
collaboration with Immunex Corporation and is in pre-clinical development.
The Company`s third project is an anti-cancer antibody, which is also in
preclinical development.
"The Growth Fund Loan significantly expands our resources," said Lisa N.
Drakeman, Ph.D., Chief Executive Officer of Genmab. "We plan to use the
financing to help maintain a rapid development track for our human antibody
products."
Genmab A/S is a biotechnology company developing human antibodies to treat
a broad spectrum of life-threatening and debilitating diseases, including
cancer and chronic inflammatory conditions such as rheumatoid arthritis and
psoriasis. Human antibodies are expected to provide a treatment advantage
over other antibody based products, especially since antibodies containing
mouse proteins are likely to be rejected by the body when used over time and
can lead to allergic-type reactions. Genmab is the first Danish biotechnology
company dedicated exclusively to developing antibody products. For more
information about Genmab, visit the web site at http://www.genmab.com.
Certain statements in this press release consist of forward-looking
statements that involve risks and uncertainties including, but not limited to,
uncertainties regarding the results of clinical trials and the development of
new products. Actual results, events or performance may differ materially.

SOURCE Genmab A/S

[CountZero]

An JSK!
To BUY or not to BUY? Eindeutig BUY!!!

RESEARCH ALERT- Medarex started
NEW YORK, Nov 8 (Reuters) - Warburg Dillon Read said on Monday it began coverage of biotechnology company Medarex Inc. (NasdaqNM:MEDX - news) with a ``buy`` rating.

-- Set 12-month price target of $19 per share.

-- Said the company`s technology for making human antibodies, which bind selectively to invaders such as cancer, ``is faster and more cost effective than other currently available techniques.``

-- Said technology is being marketed to companies who use it and provide Medarex with near-term revenues in the form of licensing fees and milestone payments.


-- Sees momentum for deals in the area of antibody
therapies.
-- Medarex shares closed at 8-1/4 in Friday Nasdaq trade.

Quelle http://biz.yahoo.com/rf/991108/l6.html

CountZero

[Klaus Meier]

MEDAREX INC Nasdaq 58391610 14,625 +2,8125 +23,81%

was soll man noch sagen

[Klaus Meier]

Medarex Inc. Reiterated `Strong Buy` at Dain Rauscher Wessels


Princeton, New Jersey, Dec. 28 (Bloomberg Data) -- Medarex Inc. (MEDX US)
was reiterated ``strong buy`` by analyst Todd R. Nelson at Dain Rauscher
Wessels.
NYSE

[CountZero]

Hallo Klaus,

nachdem nur wir beide im letzten Monat was zu sagen haben, kann ich dich ja gleich auch persönlich anreden.

Nachdem die Aktie von Mitte November bis heute über 300% zugelegt hat, kann ich mir nur schwer vorstellen, das es auch so weiter geht. Richtige News hat es in den letzten Wochen nicht gegeben. Die Presse in den USA ist so langam auf den Wert aufmerkam geworden.
http://www.medarex.com/researchF.html
Aber das hat alles noch keine Substanz. Die Produkte sind immer noch in der klinischen Forschung und mit den Mäusen sind noch keine Mäuse verdient worden.

Obwohl der Kurs Gestern auf 32,75$ gestiegen ist, glaube ich, das der Wert sich erst einmal bei 30$ einpendelt. Wenn dann die Produkte an den Markt gehen, dann wird es noch mal interessant. Bis dahin ist die Aktie für mich eher ein `HOLD` als ein `strong buy`.

CountZero

[Klaus Meier]

Ist schon richtig - ein wenig Vorsicht ist immer nach so einem starken anstieg angebracht- die news von heute :
MEDAREX INC Nasdaq 58391610 36,25 +3,50 +10,69%

Medarex and IDM Announce Broad Antibody Development Agreement and Anti-CTLA-4 Cancer Vaccine Partnership
Wednesday, December 29, 1999 07:00 AM Mail this article to a friend


PARIS and ANNANDALE, N.J., Dec. 29 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX, news, msgs) and IDM, a privately held European biotechnology company, announced today the formation of a collaboration involving the use of Medarex`s HuMAb-Mouse(TM) technology for the generation of fully human antibodies. Under the terms of the agreement, Medarex could receive research payments, license fees and milestone payments as well as royalties on future commercial sales. The agreement allows IDM, Medarex`s fourteenth HuMAb-Mouse partner, to access the antibody development technology for multiple targets.

In addition, IDM has also become Medarex`s first partner for CTLA-4 Blockade technology to enhance cancer vaccines. IDM intends to pursue an anti-CTLA-4 approach in conjunction with its proprietary DendritophagesTM as a cellular vaccine for the treatment of melanoma and prostate cancers.

"Medarex has a unique platform of powerful antibody technologies," stated Jean-Loup Romet-Lemonne, President and CEO of IDM. "This synergistic partnership exploits both companies` expertise in immunology."

"Combining an anti-CTLA-4 approach with IDM`s innovative Dendritophages could amplify the power of cellular cancer vaccines," said Donald L. Drakeman, President and CEO of Medarex.

CTLA-4, a receptor protein found on the surface of T-cells, is believed to suppress the attack by immune system killer cells. As a novel therapeutic technology, blocking CTLA-4 may allow the immune system to more vigorously attack foreign pathogens and cancers.

Dendritophages are the basis for IDM`s cellular vaccines. Dendritophages, dedicated cells for antigen presentation, process and present specific tumor antigens on their cell surface after co-culture in vitro with fragments of the patient`s tumor cells. Once reinjected, Dendritophages may initiate a powerful immune response, helping the patient reject the tumor and prevent tumor recurrence.

Medarex`s HuMAb-Mouse technology is a transgenic mouse system that creates high-affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months. Through its GenPharm subsidiary, Medarex creates and develops human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services.

IDM is a biopharmaceutical company developing new cell and gene therapy treatments to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. IDM`s products are designed to boost the immune system, destroy residual tumor cells, and immunize patients to prevent tumor recurrence. For more information about the company visit its web site at http://www.idm-biotech.com.

Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. The Company has developed a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse(TM) system for the creation of high-affinity human antibodies; Bispecific antibodies, which enhance and direct the body`s own immune system to fight disease; and immunotoxin technology. Medarex has seven products in clinical development for the treatment of cancers and leukemia, autoimmune diseases and ophthalmic conditions. For more information about the company visit its web site at http://www.medarex.com.

Certain statements in this press release consist of forward-looking statements that involve risks and uncertainties including, but not limited to, uncertainties regarding the development of new products and business opportunities, the receipt of future payments, and the continuation of business partnerships. Actual results, events or performance may differ materially.

SOURCE Medarex, Inc.

CONTACT: Donald L. Drakeman, President and CEO of Medarex, Inc., 908-713-6001; or Kimberly Hofman of Middleberg + Associates, for Medarex, Inc., 212-888-6610, ext. 544, or [e-mail]


Quote for referenced ticker symbols: MEDX

© 1999, PR Newswire

[Klaus Meier]

Das ding bleibt heiss- in usa spricht man von Ziel 85 $ bis 125 $
meine ein wenig übertrieben aber wenn man so manche anderen sieht yahoo,amazon,intershop und und und warum nicht 100 Euro
heute :
MEDAREX INC Nasdaq 58391610 40,00 +7,25 +22,14%

[hiddenclaim2]

Spinnen die Germanen ???

In FRA werden Kurse mit über 34% Aufschlag bezahlt
und das bei sehr hohem Volumen !?
Ich versteh die Börsenwelt nicht mehr!!
Gruß hd2

[Klaus Meier]

ist den keiner hier der heute gekauft hat - und uns sagt warum es so abgeht-

[del piero]

die party geht weite +14% in usa !

[Juergen23]

Medarex war zwischenzeitlich auch besonders im Aktionär empfohlen worden.